Ticker

No recent analyst price targets found for CYCN.

Latest News for CYCN

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN)

NEW YORK, April 2, 2026 /PRNewswire/ -- Class Action Attorney  Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Cyclerion Therapeutics, Inc. (NASDAQ:…

PRNewsWire • Apr 2, 2026
CYCN Stock Alert: Halper Sadeh LLC is Investigating Whether Cyclerion Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) and Korsana Biosciences, Inc. Upon closing of the proposed transaction, Cyclerion shareholders are expected to own approximately 1.5% of the combined company. Halper Sadeh encourages Cyclerion shareholders to click here to learn more about their rights and options or…

Business Wire • Apr 2, 2026
Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders

MILWAUKEE, April 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Korsana. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

PRNewsWire • Apr 1, 2026
Cyclerion Therapeutics Stock Soars 350% On Korsana Merger, $380 Million Financing

Under the deal, the combined company is expected to operate as Korsana Biosciences and trade on the Nasdaq under the ticker symbol KRSA. The move appears to be driving enthusiasm because it gives public-market investors exposure to Korsana's lead program, KRSA-028, a next-generation shuttled monoclonal antibody targeting amyloid beta for the treatment of Alzheimer's disease.

Benzinga • Apr 1, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for CYCN.

No House trades found for CYCN.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top